Treatment of Helicobacter pylori Infection 2015

Helicobacter

Volumn 20, Issue , 2015, Pages 54-61

  O'Connor, Anthony ^a   Gisbert, Javier P ^b,c   O'Morain, Colm ^d   Ladas, Spiros ^e  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e KAT HOSPITAL   (Greece)

Author keywords

Antimicrobial susceptibility testing; Compliance; First line; Peptic ulcer disease; Resistance; Second line

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ESOMEPRAZOLE; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; ANTIINFECTIVE AGENT;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ARTICLE; BIFIDOBACTERIUM INFANTIS; COMBINATION CHEMOTHERAPY; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS GASSERI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; RETREATMENT; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEALTH; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GLOBAL HEALTH; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROBIOTICS;

EID: 84941569326     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12258     Document Type: Article

References (74)

1. Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol 2014;20:14973-85.
2. Yoon KH, Park SW, Lee SW, Kim BJ, Kim JG. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. J Korean Med Sci 2014;29:1240-6.
3. Kawai T, Takahashi S, Suzuki H, Sasaki H, Nagahara A, Asaoka D, et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol 2014;29(Suppl 4):29-32.
4. Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol 2015;49(6):468-71.
5. Onyekwere CA, Odiagah JN, Igetei R, Emanuel AO, Ekere F, Smith S. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. World J Gastroenterol 2014;20:3615-9.
6. Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol 2014;26:1380-4.
7. Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K, Furuta T. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. Helicobacter 2014;19:312-8.
8. Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, Lee WS, Joo YE, Kim HS, Choi SK, Rew JS. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014;109:1595-602.
9. Gisbert JP, Barrio J, Modolell I, et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015;60:458-64.
10. Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical first-line and second-line treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-5.
11. Zhou L, Zhang J, Chen M, Hou X, Li Z, Song Z, He L, Lin S. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol 2014;109:535-41.
12. Tsay FW, Wu DC, Kao SS, et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter 2015;20:71-7.
13. Dolapcioglu C, Koc-Yesiltoprak A, Ahishali E, Kural A, Dolapcioglu H, Soylu A, Dabak R. Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting. Int J Clin Exp Med 2014;7:2324-8.
14. Chaabane NB, Al-Adhba HS. Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial. Indian J Gastroenterol 2015;34:68-72.
15. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2015; Jan 7 Epub ahead of print.
16. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9.
17. De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014;63:748-52.
18. Heo J, Jeon SW, Jung JT, et al. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis 2014;46:980-4.
19. Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015;21:351-9.
20. Kim SY, Park DK, Kwon KA, Kim KO, Kim YJ, Chung J. Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2014;64:260.
21. Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother 2014;58:5936-42.
22. Ang TL, Fock KM, Song M, Ang D, Kwek AB, Ong J, Tan J, Teo EK, Dhamodaran S. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first line treatment for Helicobacter pylori infection. J Gastroenterol Hepatol 2015;30(7):1134-9.
23. Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging the dogma: a randomized trial of standard vs. half-dose concomitant non-bismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:179-88.
24. Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: Efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015;20:79-88.
25. Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter 2014;19:207-13.
26. Metanat HA, Valizadeh SM, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Bari Z. Comparison between 10- and 14-day hybrid regimens for Helicobacter pylori eradication: a randomized clinical trial. Helicobacter 2015;20(4):299-304.
27. Biernat MM, Poniewierka E, Blłaszczuk J, Czapla L, Kempiński R, Ksidzyna D, Grabińska J, Bińkowska A, Megraud F, Gościniak G. Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland. Arch Med Sci 2014;10:505-9.
28. Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014;59:1235-43.
29. Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter 2014;19:214-20.
30. Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109:485-95.
31. Song Z, Zhang J, He L, Chen M, Hou X, Li Z, Zhou L. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis 2014;46:1077-81.
32. Wüppenhorst N, Draeger S, Stüger HP, Hobmaier B, Vorreiter J, Kist M, Glocker EO; ResiNet Study Group. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother 2014;69:3127-33.
33. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male United States Veterans. Clin Gastroenterol Hepatol 2015.
34. Picoli SU, Mazzoleni LE, Fernández H, De Bona LR, Neuhauss E, Longo L, Prolla JC. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. Rev Inst Med Trop Sao Paulo 2014;56:197-200.
35. Peretz A, Paritsky M, Nasser O, Brodsky D, Glyatman T, Segal S, On A. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. J Antibiot (Tokyo) 2014;67:555-7.
36. Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clin Microbiol Infect 2014;20:1127-33.
37. Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian J Med Microbiol 2014;32:408-13.
38. Cheng A, Sheng WH, Liou JM, Wang HP, Wu MS, Lin JT, Chang SC. Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan. J Microbiol Immunol Infect 2015;48:72-9.
39. Karczewska E, Klesiewicz K, Wojtas-Bonior I, Skiba I, Sito E, Czajecki K, Zwolińska-Wciso M, Budak A. Levofloxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006-2012. Acta Pol Pharm 2014;71:477-83.
40. Pandya HB, Agravat HH, Patel JS, Sodagar NR. The evolution of Helicobacter pylori antibiotic resistance over 10 years in Greece. Digestion 2014;90:229-31.
41. Phan TN, Santona A, Tran VH, Tran TN, Le VA, Cappuccinelli P, Rubino S, Paglietti B. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole resistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents 2015;45:244-8.
42. Selgrad M, Tammer I, Langner C, Bornschein J, Meißle J, Kandulski A, Varbanova M, Wex T, Schlüter D, Malfertheiner P. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014;20:16245-51.
43. Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A Triple and Quadruple therapy with Doxycycline and bismuth for first-line treatment of Helicobacter pylori infection: a pilot study. Helicobacter 2015. doi: 10.1111/hel.12209. [Epub ahead of print].
44. Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day Moxifloxacin-based triple therapy as second-line eradication for Helicobacter pylori Infection. Gut Liv 2015;9(4):478-85.
45. Harb AH, El Reda ZD, Sarkis FS, Chaar HF, Sharara AI. Efficacy of reduced-dose regimen of a capsule containing bismuth subcitrate, metronidazole, and tetracycline given with amoxicillin and esomeprazole in the treatment of Helicobacter pylori infection. United European Gastroenterol J 2015;3:95-6.
46. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014;40:171-7.
47. Ierardi E, Giangaspero A, Losurdo G, Giorgio F, Amoruso A, De Francesco V, Di Leo A, Principi M. Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. J Gastrointestin Liver Dis 2014;23:367-70.
48. Zhang Y, Gao W, Cheng H, Zhang X, Hu F. Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study. Helicobacter 2014;19:382-6.
49. Mansour-Ghanaei F, Joukar F, Naghipour MR, Forouhari A, Saadat SM. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol 2015;21:661-6.
50. Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter 2014;19:372-81.
51. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol 2014;49:528-38.
52. Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf 2014;23:443-55.
53. Rakici H, Ayaz T, Akdogan RA, Bedir R. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. Digestion 2014;90:261-4.
54. Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int 2014;2014:158520.
55. Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis 2015;47:114-8.
56. Liang CM, Cheng JW, Kuo CM, Chang KC, Wu KL, Tai WC, Chiu KW, Chiu SS, Lin MT, Hu TH, Chuah SK. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J 2014;37:326-30.
57. Tai WC, Lee CH, Chiou SS, et al. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS ONE 2014;9:e105822.
58. Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015;41:768-75.
59. Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis 2015;47:108-13.
60. Chung KH, Lee DH, Jin E, Cho Y, Seo JY, Kim N, Jeong SH, Kim JW, Hwang JH, Shin CM. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea. Gut Liv 2014;8:605-11.
61. Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung HC. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. World J Gastroenterol 2014;20:6932-8.
62. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895-905.
63. Ren L, Lu H, Li HY, Zhu LY, Xu XQ, Gu LY, Ge ZZ, Li XB. New dual therapy for primary treatment of Helicobacter pylori infection: a prospective randomized study in Shanghai, China. J Dig Dis 2014;15:622-7.
64. Attumi TA, Graham DY. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter 2014;19:319-22.
65. Thiraworawong T, Spinler JK, Werawatganon D, Klaikeaw N, Venable SF, Versalovic J, Tumwasorn S. Anti-inflammatory properties of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter 2014;19:144-55.
66. Francavilla R, Polimeno L, Demichina A, et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol 2014;48:407-13.
67. Dore MP, Cuccu M, Pes GM, Manca A, Graham DY. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med 2014;9:649-54.
68. Zhu R, Chen K, Zheng YY, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20:18013-21.
69. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS ONE 2014;9:e111030.
70. Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med 2015;9:707-16.
71. Xie Y, Zhu Y, Zhou H, et al. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol 2014;20:11415-21.
72. Hajaghamohammadi A, Safiabadi Tali SH, Samimi R, Oveisi S, Kazemifar AM. Low dose furazolidone for eradication of H. pylori instead of clarithromycin: a clinical trial. Glob J Health Sci 2014;7:235-9.
73. Bruce MG, Bruden DL, Morris JM, et al. Reinfection after successful eradication of Helicobacter pylori in three different populations in Alaska. Epidemiol Infect 2015;143:1236-46.
74. Kim SY, Hyun JJ, Jung SW, Koo JS, Yim HJ, Lee SW. Helicobacter pylori recurrence after first- and second-line eradication therapy in Korea: the problem of recrudescence or reinfection. Helicobacter 2014;19:202-6.